Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) – Jefferies Group issued their Q1 2018 earnings per share (EPS) estimates for Intercept Pharmaceuticals in a note issued to investors on Wednesday. Jefferies Group analyst M. Yee forecasts that the biopharmaceutical company will post earnings of ($3.30) per share for the quarter. Jefferies Group has a “Buy” rating and a $135.00 price objective on the stock. Jefferies Group also issued estimates for Intercept Pharmaceuticals’ Q2 2018 earnings at ($3.17) EPS, Q3 2018 earnings at ($3.08) EPS, Q4 2018 earnings at ($2.85) EPS and FY2019 earnings at ($10.16) EPS.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($3.48) by $0.59. The business had revenue of $41.33 million during the quarter, compared to analysts’ expectations of $36.95 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The firm’s quarterly revenue was up 697.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($3.59) earnings per share.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/11/02/equities-analysts-offer-predictions-for-intercept-pharmaceuticals-inc-s-q1-2018-earnings-icpt.html.

Other analysts have also issued research reports about the company. Wedbush restated a “buy” rating on shares of Intercept Pharmaceuticals in a report on Monday, July 31st. BidaskClub upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 13th. Zacks Investment Research upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $136.00 target price for the company in a report on Tuesday, July 11th. Cowen and Company restated a “buy” rating and set a $112.00 target price (down previously from $232.00) on shares of Intercept Pharmaceuticals in a report on Friday, September 22nd. Finally, Seaport Global Securities restated a “buy” rating and set a $136.00 target price on shares of Intercept Pharmaceuticals in a report on Friday, October 6th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Intercept Pharmaceuticals has a consensus rating of “Hold” and an average price target of $153.76.

A number of hedge funds have recently modified their holdings of the stock. PNC Financial Services Group Inc. raised its stake in Intercept Pharmaceuticals by 0.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,020 shares of the biopharmaceutical company’s stock worth $229,000 after acquiring an additional 14 shares during the last quarter. Public Employees Retirement Association of Colorado raised its stake in Intercept Pharmaceuticals by 1.1% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 4,111 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 43 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in Intercept Pharmaceuticals by 1.8% in the 2nd quarter. Janney Montgomery Scott LLC now owns 3,435 shares of the biopharmaceutical company’s stock worth $416,000 after acquiring an additional 62 shares during the last quarter. WFG Advisors LP raised its stake in Intercept Pharmaceuticals by 16.4% in the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 125 shares during the last quarter. Finally, Oppenheimer & Co. Inc. raised its stake in Intercept Pharmaceuticals by 9.0% in the 1st quarter. Oppenheimer & Co. Inc. now owns 2,152 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 178 shares during the last quarter. Institutional investors own 82.81% of the company’s stock.

In related news, CEO Mark Pruzanski sold 1,532 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $58.87, for a total value of $90,188.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO David Shapiro sold 1,250 shares of the firm’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $117.43, for a total value of $146,787.50. Following the completion of the transaction, the chief marketing officer now owns 45,812 shares of the company’s stock, valued at approximately $5,379,703.16. The disclosure for this sale can be found here. Insiders sold a total of 4,069 shares of company stock valued at $325,974 in the last 90 days. 9.20% of the stock is currently owned by company insiders.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Earnings History and Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.